よむ、つかう、まなぶ。
07 参考資料２－１ 帯状疱疹ワクチン ファクトシート (53 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36248.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第21回 11／9）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
123. Lai YC, Yew YW. Severe autoimmune adverse events post herpes zoster vaccine: A case-control
study of adverse event in a national database. J Drugs Dermatol 2015; 14(7): 681-4.
124. Yao CA, Chen LK, Huang KC. The immunogenicity and safety of zoster vaccine in
Taiwanese adults. Vaccine 2015; 33: 1515-7.
125. Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S, Baxter
R, Nordin J, Daley MF, Jackson L, Jacobsen SJ; Vaccine Safety Datalink (VSD) Team.
Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety
Datalink study. J Intern Med 2012; 271(5): 510-20.
126. Sutradhar SC, Wang WW, Schlienger K, Stek JE, Xu J, Chan IS, Silber JL. Comparison of
the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in
adults 60 years old or older. Clin Vaccine Immunol 2009; 16(5): 646-52.
127. Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS,
Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in subject with a
history of herpes zoster. Vaccine 2010; 28(25): 4204-9.
128. Chacón GR, Sinha AA. Bullous pemphigoid after herpes zoster vaccine administration:
association or coincidence? J Drugs Dermatol 2011; 10(11): 1328-30.
129. Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, Wang WW, Chan IS,
Annunziato PW, Parrino J. Safety and tolerability of zoster vaccine in adults ≥60 years old.
Hum Vaccines 2011; 7(11): 1130-6.
130. Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD,
Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF,
Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA,
Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan
IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles
Prevention Study Group. Safety of zoster vaccine in elderly ddults following documented
herpes zoster. J Infect Dis 2013; 208: 559-63.
131. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis
JR. Association between vaccination for herpes zoster and risk of herpes zoster infection
among older patients with selected immune-mediated diseases. JAMA 2012; 308(1): 43-9.
132. Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, Baxter R, Donahue JG,
Naleway AL, Jacobsen SJ. Risk of herpes zoster and disseminated varicella zoster in
patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin
Proc 2015; 90(7): 865-73.
133. Russell AF, Parrino J, Fisher CL Jr, Spieler W, Stek JE, Coll KE, Su SC, Xu J, Li X,
Schlienger K, Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in
subjects on chronic/maintenance corticosteroids. Vaccine 2015; 33(27): 3129-34.
48
study of adverse event in a national database. J Drugs Dermatol 2015; 14(7): 681-4.
124. Yao CA, Chen LK, Huang KC. The immunogenicity and safety of zoster vaccine in
Taiwanese adults. Vaccine 2015; 33: 1515-7.
125. Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S, Baxter
R, Nordin J, Daley MF, Jackson L, Jacobsen SJ; Vaccine Safety Datalink (VSD) Team.
Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety
Datalink study. J Intern Med 2012; 271(5): 510-20.
126. Sutradhar SC, Wang WW, Schlienger K, Stek JE, Xu J, Chan IS, Silber JL. Comparison of
the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in
adults 60 years old or older. Clin Vaccine Immunol 2009; 16(5): 646-52.
127. Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS,
Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in subject with a
history of herpes zoster. Vaccine 2010; 28(25): 4204-9.
128. Chacón GR, Sinha AA. Bullous pemphigoid after herpes zoster vaccine administration:
association or coincidence? J Drugs Dermatol 2011; 10(11): 1328-30.
129. Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, Wang WW, Chan IS,
Annunziato PW, Parrino J. Safety and tolerability of zoster vaccine in adults ≥60 years old.
Hum Vaccines 2011; 7(11): 1130-6.
130. Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD,
Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF,
Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA,
Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan
IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles
Prevention Study Group. Safety of zoster vaccine in elderly ddults following documented
herpes zoster. J Infect Dis 2013; 208: 559-63.
131. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis
JR. Association between vaccination for herpes zoster and risk of herpes zoster infection
among older patients with selected immune-mediated diseases. JAMA 2012; 308(1): 43-9.
132. Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, Baxter R, Donahue JG,
Naleway AL, Jacobsen SJ. Risk of herpes zoster and disseminated varicella zoster in
patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin
Proc 2015; 90(7): 865-73.
133. Russell AF, Parrino J, Fisher CL Jr, Spieler W, Stek JE, Coll KE, Su SC, Xu J, Li X,
Schlienger K, Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in
subjects on chronic/maintenance corticosteroids. Vaccine 2015; 33(27): 3129-34.
48